Speaking of Fragilex, the trofinetide phase 2 developed by Neuren no longer exists in the Acadia pipeline, are they aiming directly at ACP-2591?
There's no point mucking around. Straight to the best asset. Everyone talks about the enormous costs of trials so why double up. Quite the vote of confidence in 2591 to take it over an approved drug.
More importantly, and forgive me if I am wrong. Since Acadia seem to have dropped developing Trofinetide in other conditions, does it seem to remove the consternation about 2591 being limited in its scope because of this condition in the agreement between Acadia and Neuren:
"Neuren has an obligation not to develop NNZ-2591 or any other product for North America in an indication for which Acadia develops trofinetide, except for Phelan-McDermid, Pitt Hopkins, Angelman and Prader-Willi syndromes."
Can the wise heads who discussed this issue give their view? Is 2591 unshackled now?
Speaking of Fragilex, the trofinetide phase 2 developed by...
-
- There are more pages in this discussion • 790 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.21 |
Change
-1.060(4.98%) |
Mkt cap ! $2.583B | |||
| Open | High | Low | Value | Volume |
| $20.98 | $21.06 | $20.14 | $6.308M | 308.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3926 | $20.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.21 | 388 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |